search
Back to results

Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation (NU-BURST)

Primary Purpose

Neck Pain, Upper Limb Pain

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Spinal Cord Stimulation (SCS)
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neck Pain focused on measuring Neck Pain, Upper Limb Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is able to provide informed consent to participate in the study;
  • Subject is 18 years of age or older;
  • Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, and injections;
  • Subject has failed to respond to medial branch blocks;
  • Subject diagnosed with chronic predominant intractable neck pain with or without radiation down to arm/shoulder/upper back;
  • Subject has neck pain intensity of at least 6.0 cm out of 10.0 cm on the average neck pain VAS at baseline (according to the last 3 days of the baseline pain diary);
  • Subject is on stable pain medications with a total opioid equivalent of120 mg or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until activation of the permanently implanted SCS device;
  • Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
  • Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
  • Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study

Exclusion Criteria:

  • Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, moderate or severe cervical stenosis determined by existing or new MRI scan performed as part of standard of care, mechanical neck pain originating from cervical facet joint syndrome, post-herpetic neuralgia, spondylolisthesis, retrolisthesis, CRPS (Chronic Regional Pain Syndrome) or uncontrolled diabetes mellitus;
  • Subject with significant scoliosis even if surgically corrected;
  • Subject is currently participating in a clinical investigation that includes an active treatment arm;
  • Subject has been implanted with or participated in a trial period for a neurostimulation system;
  • Subject has an infusion pump;
  • Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
  • Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
  • Subject is immunocompromised;
  • Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
  • Subject has history of cancer requiring active treatment in the last 12 months;
  • Subject has an existing medical condition that is likely to require the use of diathermy in the future;
  • Subject has documented history of allergic response to titanium or silicone;
  • Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
  • Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test);
  • Subject has life expectancy of less than 1 year;
  • Subject is involved in an injury claim under current litigation

Sites / Locations

  • Southmead hospitalRecruiting
  • Guy's St. Thomas HospitalRecruiting
  • University Hospital Southampton NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

study patients

Arm Description

Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.

Outcomes

Primary Outcome Measures

Visual Analog Scale (VAS) for pain
Golden standard self-evaluation of pain intensity
Visual Analog Scale for pain
Golden standard self-evaluation of pain intensity
Visual Analog Scale for pain
Golden standard self-evaluation of pain intensity
Visual Analog Scale for pain
Golden standard self-evaluation of pain intensity
Visual Analog Scale for pain
Golden standard self-evaluation of pain intensity

Secondary Outcome Measures

EQ-5D - 5L (European Quality of Life) (5D-dimensions); (5L levels)
Self reported questionnaire on quality of life
EQ-5D - 5L
Self reported questionnaire on quality of life
EQ-5D - 5L
Self reported questionnaire on quality of life
EQ-5D - 5L
Self reported questionnaire on quality of life
EQ-5D - 5L
Self reported questionnaire on quality of life
ONDI
Disability questionnaire
ONDI (Oswestry neck disability index)
Disability questionnaire
ONDI
Disability questionnaire
ONDI
Disability questionnaire
ONDI
Disability questionnaire
Patient Global Impression of Change
questionnaire on patient satisfaction with therapeutic outcome
Patient Global Impression of Change
questionnaire on patient satisfaction with therapeutic outcome
Patient Global Impression of Change
questionnaire on patient satisfaction with therapeutic outcome
Patient Global Impression of Change
questionnaire on patient satisfaction with therapeutic outcome
Headache Impact Test
Questionnaire on headache burden
Headache Impact Test
Questionnaire on headache burden
Headache Impact Test
Questionnaire on headache burden
Headache Impact Test
Questionnaire on headache burden
Headache Impact Test
Questionnaire on headache burden
Hospital Anxiety and Depression
Questionnaire on anxiety and depression
Hospital Anxiety and Depression
Questionnaire on anxiety and depression
Hospital Anxiety and Depression
Questionnaire on anxiety and depression
Hospital Anxiety and Depression
Questionnaire on anxiety and depression
Hospital Anxiety and Depression
Questionnaire on anxiety and depression

Full Information

First Posted
May 11, 2017
Last Updated
April 6, 2021
Sponsor
Abbott Medical Devices
search

1. Study Identification

Unique Protocol Identification Number
NCT03159169
Brief Title
Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation
Acronym
NU-BURST
Official Title
Treatment of Neck and Upper (NU) Limb Pain Using BurstDR Stimulation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 15, 2018 (Actual)
Primary Completion Date
April 2022 (Anticipated)
Study Completion Date
August 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, open label, multicenter feasibility study to evaluate the safety and therapeutic efficacy of BurstDRTM SCS in treating chronic neck pain with or without radiation down to arm/shoulder/upper back
Detailed Description
Subjects diagnosed with chronic intractable neck pain with or without radiation down to arm/shoulder/upper back will be considered for inclusion in this study. After baseline evaluation, subjects will undergo a SCS trial using the Abbott Invisible Trial system. At the end of the SCS trial, subjects experiencing at least 50% pain relief, according to average neck VAS (calculated by the average of last 3 days on the pain diary), will be considered for permanent implant and further participation in the study. Pain intensity, quality of life, disability, headache severity, sleep quality, patient satisfaction, anxiety, depression, stimulation sensation and medication usage assessments will be performed at baseline, after SCS trial and at the 3, 6 and 12 month follow up visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neck Pain, Upper Limb Pain
Keywords
Neck Pain, Upper Limb Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
study patients
Arm Type
Experimental
Arm Description
Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
Intervention Type
Device
Intervention Name(s)
Spinal Cord Stimulation (SCS)
Intervention Description
Implantation of SCS electrodes and stimulator according to clinical standards
Primary Outcome Measure Information:
Title
Visual Analog Scale (VAS) for pain
Description
Golden standard self-evaluation of pain intensity
Time Frame
baseline
Title
Visual Analog Scale for pain
Description
Golden standard self-evaluation of pain intensity
Time Frame
end of SCS trial (up to two weeks after electrodes implantation)
Title
Visual Analog Scale for pain
Description
Golden standard self-evaluation of pain intensity
Time Frame
3 months post permanent implant
Title
Visual Analog Scale for pain
Description
Golden standard self-evaluation of pain intensity
Time Frame
6 months post permanent implant
Title
Visual Analog Scale for pain
Description
Golden standard self-evaluation of pain intensity
Time Frame
12 months post permanent implant
Secondary Outcome Measure Information:
Title
EQ-5D - 5L (European Quality of Life) (5D-dimensions); (5L levels)
Description
Self reported questionnaire on quality of life
Time Frame
baseline
Title
EQ-5D - 5L
Description
Self reported questionnaire on quality of life
Time Frame
End of SCS trial (up to two weeks after electrodes implantation)
Title
EQ-5D - 5L
Description
Self reported questionnaire on quality of life
Time Frame
3 months post permanent implant
Title
EQ-5D - 5L
Description
Self reported questionnaire on quality of life
Time Frame
6 months post permanent implant
Title
EQ-5D - 5L
Description
Self reported questionnaire on quality of life
Time Frame
12 months post permanent implant
Title
ONDI
Description
Disability questionnaire
Time Frame
baseline
Title
ONDI (Oswestry neck disability index)
Description
Disability questionnaire
Time Frame
end of SCS trial (up to two weeks after electrodes implantation)
Title
ONDI
Description
Disability questionnaire
Time Frame
3 months post permanent implant
Title
ONDI
Description
Disability questionnaire
Time Frame
6 months post permanent implant
Title
ONDI
Description
Disability questionnaire
Time Frame
12 months post permanent implant
Title
Patient Global Impression of Change
Description
questionnaire on patient satisfaction with therapeutic outcome
Time Frame
end of SCS trial (up to two weeks after electrodes implantation)
Title
Patient Global Impression of Change
Description
questionnaire on patient satisfaction with therapeutic outcome
Time Frame
3 months post permanent implant
Title
Patient Global Impression of Change
Description
questionnaire on patient satisfaction with therapeutic outcome
Time Frame
6 months post permanent implant
Title
Patient Global Impression of Change
Description
questionnaire on patient satisfaction with therapeutic outcome
Time Frame
12 months post permanent implant
Title
Headache Impact Test
Description
Questionnaire on headache burden
Time Frame
baseline
Title
Headache Impact Test
Description
Questionnaire on headache burden
Time Frame
end of SCS trial (up to two weeks after electrodes implantation)
Title
Headache Impact Test
Description
Questionnaire on headache burden
Time Frame
3 months post permanent implant
Title
Headache Impact Test
Description
Questionnaire on headache burden
Time Frame
6 months post permanent implant
Title
Headache Impact Test
Description
Questionnaire on headache burden
Time Frame
12 months post permanent implant
Title
Hospital Anxiety and Depression
Description
Questionnaire on anxiety and depression
Time Frame
baseline
Title
Hospital Anxiety and Depression
Description
Questionnaire on anxiety and depression
Time Frame
end of SCS trial (up to two weeks after electrodes implantation)
Title
Hospital Anxiety and Depression
Description
Questionnaire on anxiety and depression
Time Frame
3 months post permanent implant
Title
Hospital Anxiety and Depression
Description
Questionnaire on anxiety and depression
Time Frame
6 months post permanent implant
Title
Hospital Anxiety and Depression
Description
Questionnaire on anxiety and depression
Time Frame
12 months post permanent implant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is able to provide informed consent to participate in the study; Subject is 18 years of age or older; Subject has failed to respond to at least 6 months of conventional treatment which may include pharmacological treatment, physical therapy, and injections; Subject has failed to respond to medial branch blocks; Subject diagnosed with chronic predominant intractable neck pain with or without radiation down to arm/shoulder/upper back; Subject has neck pain intensity of at least 6.0 cm out of 10.0 cm on the average neck pain VAS at baseline (according to the last 3 days of the baseline pain diary); Subject is on stable pain medications with a total opioid equivalent of120 mg or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose increase until activation of the permanently implanted SCS device; Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system; Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits; Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study Exclusion Criteria: Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, moderate or severe cervical stenosis determined by existing or new MRI scan performed as part of standard of care, mechanical neck pain originating from cervical facet joint syndrome, post-herpetic neuralgia, spondylolisthesis, retrolisthesis, CRPS (Chronic Regional Pain Syndrome) or uncontrolled diabetes mellitus; Subject with significant scoliosis even if surgically corrected; Subject is currently participating in a clinical investigation that includes an active treatment arm; Subject has been implanted with or participated in a trial period for a neurostimulation system; Subject has an infusion pump; Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care; Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator; Subject is immunocompromised; Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor); Subject has history of cancer requiring active treatment in the last 12 months; Subject has an existing medical condition that is likely to require the use of diathermy in the future; Subject has documented history of allergic response to titanium or silicone; Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection; Subject is a female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test); Subject has life expectancy of less than 1 year; Subject is involved in an injury claim under current litigation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lalit Venkatesan, Ph.D.
Phone
+19723098522
Email
LVenkatesan@sjm.com
First Name & Middle Initial & Last Name or Official Title & Degree
Filippo Agnesi, Ph.D.
Phone
+19725264860
Email
FAgnesi@sjm.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adnan Al-Kaisy, MD
Organizational Affiliation
Guy's St. Thomas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Southmead hospital
City
Bristol
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ann Rich
Email
Ann.Rich@nbt.nhs.uk
First Name & Middle Initial & Last Name & Degree
Nik Patel, MD
First Name & Middle Initial & Last Name & Degree
Sarah Love-Jones, MD
Facility Name
Guy's St. Thomas Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samuel Wesley
Phone
02071 883237
Email
Samuel.Wesley@gstt.nhs.uk
First Name & Middle Initial & Last Name & Degree
Adnan Al-Kaisy, MD
First Name & Middle Initial & Last Name & Degree
Stefano Palmisani, MD
First Name & Middle Initial & Last Name & Degree
David Pang, MD
Facility Name
University Hospital Southampton NHS Foundation Trust
City
Southampton
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Beveridge
Email
Michelle.Beveridge@uhs.nhs.uk
First Name & Middle Initial & Last Name & Degree
Girish Vajramani, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33387056
Citation
Al-Kaisy A, Vajramani G, Love-Jones S, Patel NK, Royds J, Palmisani S, Pang D, Wesley S, Park HJ, Raza A, Agnesi F. Multicentre, clinical trial of burst spinal cord stimulation for neck and upper limb pain NU-BURST: a trial protocol. Neurol Sci. 2021 Aug;42(8):3285-3296. doi: 10.1007/s10072-020-04907-3. Epub 2021 Jan 2.
Results Reference
derived

Learn more about this trial

Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation

We'll reach out to this number within 24 hrs